This post is presented by our media partner Psychedelic News Wire
View the original article here.
Post-traumatic stress disorder is a mental health disorder caused by an extremely terrifying or stressful event, either by an individual witnessing it or being a part of it. This disorder may last anywhere between months to years, with individuals experiencing intense physical and emotional reactions when the memories of trauma are unearthed by triggers.
Estimates show that in the United Kingdom, 1 in 10 individuals will experience post-traumatic stress disorder in their lifetime. Currently, roughly 30% of patients who suffer from severe mental health conditions find that traditional therapies aren’t effective for them.
Now a team of researchers in Cambridgeshire are carrying out trials looking into the potential benefits of psychedelics and empathogens in treating post-traumatic stress disorder (PTSD).
The researchers are considering psychedelic use because the drugs are known to alter how an individual perceives reality. These drugs, also referred to as hallucinogens, make an individual hear, feel, and see things that don’t exist. Additionally, psychedelics are known to target certain areas of the brain, changing their processing of sensory input.
The team is a collaboration between Cambridgeshire and Peterborough NHS Foundation Trust, the University of Cambridge, and Cambridge University Hospital’s NHS Foundation Trust. Those involved include research staff and clinicians from the NIHR Cambridge Clinical Research Facility and the Windsor Research Unit.
The researchers, whose initiative is focused on mental health treatment, has obtained a Home Office license to carry out the trials. Their objective is to help patients who’ve gained no benefit from conventional treatments like antidepressants and talk therapy.
Various studies have already shown that some psychoactive drugs, when administered by trained specialists in controlled environments, can enhance quality of life and aid in recovery.
The researchers’ initial study has been sponsored by Transcend Therapeutics and will focus on assessing the effects of a rapid-acting neuroplastogen dubbed TSND-201, on patients with PTSD. TSND-201 is a non-hallucinogenic formulation which the researchers hope could provide a new avenue of hope for patients who’ve not benefitted from traditional treatments.
Transcend Therapeutics is a neuroscience-focused clinical-stage firm focused on developing psychoactive drugs for neuropsychiatric illnesses.
Affiliated assistant professor at the University of Cambridge, Dr. Liliana Galindo, stated that she was optimistic about the potential of this study in addressing persistent mental conditions. Galindo, who’s also a consultant psychiatrist, added that they were excited to join the growing field of psychedelic research with this new collaboration and help to develop a new generation of neuropsychiatric therapies.
With many other entities, such as atai Life Sciences N.V. (NASDAQ: ATAI), engaged in studying the therapeutic potential of psychedelics, the likelihood that approved treatments made from these substances become available soon is high.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com
PsychedelicNewsWire is powered by IBN
This post was originally published by our media partner here.
